Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition

[1]  Si Eun Kim,et al.  Amyloid involvement in subcortical regions predicts cognitive decline , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Keith A. Johnson,et al.  PET staging of amyloidosis using striatum , 2018, Alzheimer's & Dementia.

[3]  W. Jagust,et al.  Subthreshold Amyloid Predicts Tau Deposition in Aging , 2018, The Journal of Neuroscience.

[4]  J. Sepulcre,et al.  In vivo staging of regional amyloid deposition , 2017, Neurology.

[5]  A. Fleisher,et al.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease , 2017, Alzheimer's & dementia.

[6]  J. Attems,et al.  Interactions of pathological proteins in neurodegenerative diseases , 2017, Acta Neuropathologica.

[7]  Clifford R. Jack,et al.  Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART) , 2017, Acta Neuropathologica.

[8]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta neuropathologica communications.

[9]  W. Klunk,et al.  Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection , 2016, Acta Neuropathologica Communications.

[10]  Zein Al-Atrache,et al.  CHLAMYDIA PNEUMONIAE-INFECTED ASTROCYTES ALTER THEIR EXPRESSION OF ADAM10, BACE1, AND PRESENILIN-1 PROTEASES , 2016, Alzheimer's & Dementia.

[11]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[12]  Alzheimer’s Association,et al.  2016 Alzheimer's disease facts and figures , 2016, Alzheimer's & Dementia.

[13]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[14]  Kerstin Heurling,et al.  [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β pathology , 2015, Alzheimer's & Dementia.

[15]  Clifford R. Jack,et al.  Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.

[16]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[17]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[18]  L. Thurfjell,et al.  Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  C. V. von Arnim,et al.  Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[20]  C. Jack,et al.  Cerebral amyloid PET imaging in Alzheimer’s disease , 2013, Acta Neuropathologica.

[21]  J. Attems,et al.  Pathology of clinical and preclinical Alzheimer’s disease , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[22]  Lucie Yang,et al.  Brain amyloid imaging--FDA approval of florbetapir F18 injection. , 2012, The New England journal of medicine.

[23]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[24]  C. Rowe,et al.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[26]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[27]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[28]  I. Ferrer,et al.  Inter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortium , 2008, Acta Neuropathologica.

[29]  C. Rowe,et al.  Imaging β-amyloid burden in aging and dementia , 2007, Neurology.

[30]  I. Ferrer,et al.  Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium , 2006, Journal of neuropathology and experimental neurology.

[31]  Dietmar Rudolf Thal,et al.  Neurodegeneration in normal brain aging and disease. , 2004, Science of aging knowledge environment : SAGE KE.

[32]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[33]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[34]  P. Hof,et al.  Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. , 2001, Journal of neuropathology and experimental neurology.

[35]  H. Braak,et al.  Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. , 1999, Journal of neuropathology and experimental neurology.

[36]  H. Wiśniewski,et al.  Early amyloid -β deposits show different immunoreactivity to the amino- and carboxy-terminal regions of β-peptide in Alzheimer's disease and Down's syndrome brain , 1995, Neuroscience Letters.

[37]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[38]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[39]  C. Buckley,et al.  Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. , 2016, Journal of Alzheimer's disease : JAD.

[40]  C. Rowe,et al.  Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.

[41]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[42]  H. Wiśniewski,et al.  Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. , 1995, Neuroscience letters.

[43]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[44]  S. Al-Sarraj,et al.  Edinburgh Research Explorer Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium , 2022 .